{"id":"NCT02625623","sponsor":"EMD Serono Research & Development Institute, Inc.","briefTitle":"Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)","officialTitle":"A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-28","primaryCompletion":"2017-09-14","completion":"2019-11-13","firstPosted":"2015-12-09","resultsPosted":"2018-10-15","lastUpdate":"2020-11-24"},"enrollment":371,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","Gastric Cancer Third Line"],"interventions":[{"type":"DRUG","name":"Avelumab","otherNames":["MSB0010718C","Anti PD-L1"]},{"type":"DRUG","name":"Irinotecan","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"OTHER","name":"Best Supportive Care (BSC)","otherNames":[]}],"arms":[{"label":"Physician choice chemotherapy+Best Supportive Care (BSC)","type":"EXPERIMENTAL"},{"label":"Avelumab+BSC","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From randomization up to 627 days","effectByArm":[{"arm":"Physician Choice Chemotherapy + Best Supportive Care (BSC)","deltaMin":5,"sd":null},{"arm":"Avelumab + BSC","deltaMin":4.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8078"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":21},"locations":{"siteCount":75,"countries":["United States","Australia","Belgium","Czechia","France","Germany","Italy","Poland","South Korea","Spain"]},"refs":{"pmids":["30052729"],"seeAlso":["https://clinicaltrials.emdgroup.com/en/trial-details/?id=EMR%20100070-008","https://medical.emdserono.com/en_US/home.html"]},"adverseEventsSummary":{"seriousAny":{"events":81,"n":177},"commonTop":["Nausea","Diarrhoea","Anaemia","Decreased appetite","Vomiting"]}}